Picture of ALX Oncology Holdings logo

ALXO — ALX Oncology Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

ALX Oncology Holdings Inc reports results for the quarter ended in June - Earnings Summary

* ALX Oncology Holdings Inc  ALXO.OQ  reported a quarterly
adjusted loss of 81 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 63 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ALX Oncology Holdings Inc's reported EPS for the quarter
was a
loss of 81 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * ALX Oncology Holdings Inc shares had risen by 45.5% this
quarter and lost 45.2% so far this year.
    * The company reported a quarterly loss of $32.92 million.
    * Wall Street's median 12-month price target for ALX
Oncology
Holdings Inc is $37.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 12:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.63          -0.81          Missed
 Mar. 31 2022      -0.71          -0.60          Beat
 Dec. 31 2021      -0.62          -0.70          Missed
 Sep. 30 2021      -0.48          -0.61          Missed

Recent news on ALX Oncology Holdings

See all news